Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder Post published:May 12, 2023 Post category:Press Release
Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB Post published:May 11, 2023 Post category:Press Release
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights Post published:May 11, 2023 Post category:Press Release
Brain scanning technology to be used for clinical psychedelics trials in pioneering London start-up partnership Post published:May 11, 2023 Post category:Press Release
Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Post published:May 11, 2023 Post category:Press Release
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates Post published:May 11, 2023 Post category:Press Release
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights Post published:May 11, 2023 Post category:Press Release
MIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT Post published:May 11, 2023 Post category:Press Release
Optimi Health Granted NaturalĀ Health Product Site Licence By Health Canada Post published:May 10, 2023 Post category:Press Release
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants Post published:May 10, 2023 Post category:Press Release